Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034

American Journal of Hematology

Volumn 91, Issue 9, 2016, Pages 869-874

  Shah, Neil P ^a   Rousselot, Philippe ^b   Schiffer, Charles ^c   Rea, Delphine ^d   Cortes, Jorge E ^e   Milone, Jorge ^f   Mohamed, Hesham ^g   Healey, Diane ^g   Kantarjian, Hagop ^e   Hochhaus, Andreas ^h   Saglio, Giuseppe ⁱ  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SAINT LOUIS HOSPITAL   (France)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^g BRISTOL MYERS SQUIBB   (United States)

^h JENA UNIVERSITY HOSPITAL   (Germany)

ⁱ UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; DASATINIB; IMATINIB;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTHRALGIA; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONGESTIVE HEART FAILURE; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FOLLOW UP; GENE MUTATION; HUMAN; INTESTINE NECROSIS; LUNG EDEMA; MAJOR CLINICAL STUDY; MYALGIA; NAUSEA AND VOMITING; NECK PAIN; OVERALL SURVIVAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PULMONARY HYPERTENSION; RASH; SEPSIS; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84983070734     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24423     Document Type: Article

References (19)

1. Shah NP, Guilhot F, Cortes JE, et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: Follow-up of a phase 3 study. Blood 2014;123:2317–2324.
2. Baccarani M, Efficace F, Rosti G. Moving towards patient-centered decision-making in chronic myeloid leukemia: Assessment of quality of life and symptom burden. Haematologica 2014;99:205–208.
3. Deininger M, O'Brien SG, Guilhot F, et al. International randomized study of interferon vs sti571 (IRIS) 8-year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib clinically [Abstract]. Blood 2009;114:1126.
4. Sasaki K, Strom SS, O'Brien S, et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: Analysis of patient data from six prospective clinical trials. Lancet Haematol 2015;2:e186–e193.
5. Sprycel (dasatinib) [prescribing Information]. Princeton, NJ: Bristol-Myers Squibb; 2015.
6. Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008;26:3204–3212.
7. Shah NP, Kim DW, Kantarjian H, et al. Potent, transient inhibition of BCR–ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 2010;95:232–240.
8. National Cancer Institute: Common Terminology Criteria for Adverse Events v3.0. 2006. Available at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf.
9. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013;122:872–884.
10. Goldberg SL, Chen L, Guerin A. Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib. Curr Med Res Opin 2013;29:1075–1082.
11. Marin D, Ibrahim AR, Lucas C, et al. Assessment of BCR–ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 2012;30:232–238.
12. Hochhaus A, Kantarjian H. The development of dasatinib as a treatment for chronic myeloid leukemia (CML): From initial studies to application in newly diagnosed patients. J Cancer Res Clin Oncol 2013;139:1971–1984.
13. Hochhaus A, Muller MC, Radich J, et al. Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: Response dynamics and predictive value. Leukemia 2009;23:1628–1633.
14. Quintas-Cardama A, Cortes JE, O'Brien S, et al. Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia. Cancer 2009;115:2912–2921.
15. Hanfstein B, Muller MC, Hehlmann R, et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 2012;26:2096–2102.
16. Moslehi JJ, Deininger M. Tyrosine kinase inhibitor–associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol 2015;33:4210–4218.
17. Aichberger KJ, Herndlhofer S, Schernthaner G-H, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 2011;86:533–539.
18. Quintás-Cardama A, Kantarjian H, Cortes JE. Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk 2012;12:337–340.
19. Guilhot J, Baccarani M, Clark RE, et al. Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: A proposal by the European LeukemiaNet. Blood 2012;119:5963–5971.